Understand whats happening with Ozempic NAION lawsuits Ozempic NAION lawsuits are being coordinated through a dedicated federal multidistrict litigation (MDL No
For that reason, some people stay on a maintenance dose long-term to help maintain the effects of these medications
It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
doi: 10.3389/fphar.2026.1791206 Received 19 January 2026 Revised 13 April 2026 Accepted 14 April 2026 Published 01 May 2026 Volume 17 - 2026 Edited by Kabirullah Lutfy, Western University of Health Sciences, United States Reviewed by Marsida Kallupi, University of California, San Diego, United States Christina Merritt, University of Texas Medical Branch at Galveston, United States Updates Copyright 2026 Hrickova, Demirci, Amchova and Ruda-Kucerova
Semaglutide and the retina: Weighing evidence against concern [PMID: 40769838] Laboratory literature summary: Semaglutide and the retina: Weighing evidence against concern